The Generics Bulletin Top 50, Part One: Industry Top 10 Reshaped By Leaders’ Transformations
Perrigo Rx Divestment Sees Firm Drop Out Of Top Five As Sun Rises
A new entrant into the top five global generics and biosimilars companies shows how transformations for some of the leading off-patent players are reshaping the industry landscape, with more major changes in the pipeline. We examine the 10 leaders of the pack in the first instalment of this year’s Generics Bulletin Top 50.
